Please login to the form below

Not currently logged in
Email:
Password:

GalNAc

This page shows the latest GalNAc news and features for those working in and with pharma, biotech and healthcare.

Pfizer signs $900m-plus deal with WAVE for metabolic R&D

Pfizer signs $900m-plus deal with WAVE for metabolic R&D

This approach will be combined with a liver-targeting delivery technology in development at Pfizer that involves binding RNA drugs to the amno acid N-acetylgalactosamine (GalNAc). ... The deal gives WAVE scope to use GalNAc in certain projects that lie

Latest news

More from news
Approximately 1 fully matching, plus 0 partially matching documents found.

Latest Intelligence

  • Gene therapy Gene therapy

    targets. The overt focus on liver disease has led to one new system for delivering siRNA to the liver, called GalNAc. ... GalNAc uses a specific sugar group attached to chemically-modified siRNA to target liver cells.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Six Degrees Medical Consulting

Partnering with top global pharmaceutical companies, we push the boundaries to create meaningful, impactful and lasting learning opportunities. We leverage...

Latest intelligence

Island
Pharma’s isolated islands of innovation
With service design and technology often failing the patient, why perspective on improving outcomes need to change...
Uncertainty, austerity and Brexit
What does it mean for the life science sector?...
The Holy Grail of HCP Access
This is the data you need to gain access....

Infographics